Huangtu Decoction, within the clinic's purview, effectively treats acute upper gastrointestinal bleeding, acute coronary syndrome coupled with acute upper gastrointestinal bleeding, and instances of bleeding stemming from excessive antiplatelet or anticoagulant use. Furthermore, it addresses unexplained positive fecal occult blood tests, bleeding gastrointestinal tumors, thrombocytopenia, and other critical, acute medical conditions. Western Blotting Huangtu Decoction's efficacy in achieving hemostasis hinges on the proper dosage of Cooking Stove Earthkey, Rehmanniae Radix, and Asini Corii Colla.

Shenqi Pills, first appearing in ZHANG Zhong-jing's “Essentials from the Golden Cabinet” (Jin Kui Yao Lue) of the Han dynasty, are intended to fortify and invigorate kidney Qi, primarily used to address kidney Qi and Yang insufficiency. Modern medical understanding of kidney Qi encompasses heart function, kidney function, immune function, and more. The clinical applications of Shenqi Pills are marked by kidney deficiency, irregular fluid levels, and urinary disorders, namely oliguria, polyuria, and dysuria. infectious uveitis Shenqi Pills' clinical utility extends to the treatment of heart failure, renal failure, cardiorenal syndrome, and diuretic resistance, additionally covering chronic conditions within the endocrine, urological, orthopedic, and other degenerative disease categories. For those with a frail physique and immediate healthcare requirements, Shenqi Pills are an excellent choice of medication. Investigating the nuances of classical texts, integrating TCM and Western medical perspectives through a comparative analysis of 'pathogenesis and pathology,' and 'drug properties and pharmacology,' is a valuable and significant undertaking.

Significant transformations have occurred within the human disease spectrum, the constitutional profile, and patterns of drug use, presenting novel challenges and trends for the safety of traditional Chinese medicine (TCM). Instances of liver and kidney injury caused by non-toxic Traditional Chinese Medicine (TCM) have led to a questioning of long-held assumptions surrounding its safety, undermining public confidence in the continued development of TCM and prompting a re-evaluation of existing understanding. Within the context of globalization, it is imperative for practitioners of Traditional Chinese Medicine to thoroughly grasp the implications for safety and actively address the intricacies of safety evaluations and risk management in TCM. This paper posits that the problems and circumstances surrounding the safety of Traditional Chinese Medicine require an objective and dialectical approach, and that its usage standards need to adapt to modern realities. This paper additionally proposes a new understanding and methodology for TCM safety, comprising an innovative perspective, two evaluation models, a tri-element injury hypothesis, a four-quadrant risk decision-making process, and a five-grade safety evidence system. This aims to provide novel theories, approaches, and methods, and exemplary solutions to tackle TCM safety challenges.

In West tropical Africa, the leaves of Vernonia amygdalina Delile, commonly known as 'bitter leaf,' part of the Asteraceae family, have been traditionally used both as food and medicine for a significant period, thanks to their substantial biological activity. The past few years have brought the introduction of these items to both Southeast Asia and the provinces of Fujian and Guangdong in China. In contrast, the plant's properties within traditional Chinese medicine (TCM) are not well-understood, thus limiting its potential for combination with other Chinese medicinal herbs. 473 articles relating to V. amygdalina leaves were retrieved from PubMed, Web of Science, CNKI, Wanfang Data, and VIP databases, and a comprehensive summary of their constituents, pharmacological activity, and clinical trials was constructed. this website Antimicrobial, hypoglycemic, antihypertensive, lipid-lowering, anti-tumor, anti-inflammatory, antioxidant, and other pharmacological actions are demonstrably present in the leaves of V. amygdalina. By examining TCM theory, the leaves were ascertained to have a cold property and bitter-sweet flavor profile, affecting the spleen, liver, stomach, and large intestine. The leaves were found to clear heat, dry dampness, purge fire, remove toxins, kill insects, and prevent malaria. These can be used to treat dampness-heat diarrhea, interior heat, diabetes, malaria, insect build-up, and eczema. The recommended dosage is a daily decoction of 5-10 grams of dry leaves, and topical application of the appropriate amount of crushed fresh leaves. Traditional Chinese Medicine's lack of recognition for the properties of V. amygdalina leaves contributes to their infrequent medicinal use in China. Unveiling the medicinal essence of the leaves leads to the integration of novel exotic medicinal herbs within the Traditional Chinese Medicine framework, bolstering its resources and prompting further clinical application and research and development in Chinese herbal medicine.

Cervical radiculopathy treatment in China often involves Jingtong Granules, which is effective due to its function in activating blood, resolving stasis, and moving Qi to alleviate pain. Prolonged clinical use and accompanying research have shown the prescription to be highly effective in relieving pain in the neck, shoulder, and upper limbs, including stiffness and the tingling or crawling numbness, as well as the related pain stemming from this condition. Nonetheless, a unified perspective on the clinical utilization of Jingtong Granules remains elusive. Subsequently, to synthesize this expert consensus, first-line clinical experts and methodological specialists from every region of the country were invited. To improve clinical outcomes, reduce medication-related risks, and benefit patients, this expert consensus is predicted to promote a standardized and appropriate approach to the utilization of Jingtong Granules among clinicians. From the clinical perspective of experts and the established development standards, the indications, symptoms, advantages in the clinic, and potential negative effects of Jingtong Granules were documented. Clinical problems were documented through direct interviews with medical doctors from traditional Chinese and Western medicine, coupled with surveys on clinical implementations. A shared understanding, established by the nominal group method, resulted in the finalized clinical problem set. To address the clinical issues, the third step involved retrieving and scrutinizing the pertinent supporting evidence. The GRADE system facilitated an evaluation of evidence quality. The nominal group technique served to summarize 5 recommendation items and 3 consensus items in the fourth phase of the process. To obtain opinions and peer reviews on the consensus content, expert meetings and letter reviews were instrumental. Evidence regarding the clinical indications, effectiveness, and safety of Jingtong Granules, synthesized in the final consensus, serves as a valuable resource for clinicians in both hospitals and primary care institutions.

This research sought to determine the effectiveness and safety profile of Biling Weitong Granules in addressing stomach ache disorder. An investigation of Biling Weitong Granules' efficacy in treating digestive ailments, particularly stomach ache, was conducted by reviewing randomized controlled trials (RCTs) sourced from Chinese and English electronic databases and trial registries, spanning from database inception to June 10, 2022. Literature screening and data extraction were performed by two investigators, adhering to the established screening criteria. Employing the Cochrane risk-of-bias tool (version 20), an assessment of the risk of bias in the included studies was undertaken. With RevMan 54 and R 42.2, analyses were performed and summary estimates were produced using fixed or random effects models. The key metrics for evaluating outcomes were the visual analogue scale (VAS) scores and the scores reflecting symptoms of stomach ache disorder. The following were secondary outcome indicators: clinical recovery rate, Helicobacter pylori (Hp) eradication rate, and adverse reaction/events. A review of 2,902 cases across 27 randomized controlled trials was undertaken. A meta-analysis study assessed Biling Weitong Granules against conventional Western medicine treatments or placebo, revealing improvements in various factors: VAS scores (SMD = -190, 95% CI [-218, -161], P < 0.00001), stomach ache symptom scores (SMD = -126, 95% CI [-171, -82], P < 0.00001), clinical recovery rates (RR = 185, 95% CI [166, 208], P < 0.00001), and eradication rate of H. pylori (RR = 128, 95% CI [120, 137], P < 0.00001). In a safety evaluation of Biling Weitong Granules, nausea and vomiting, rash, diarrhea, loss of appetite, and a bitter mouth were the primary adverse effects observed; no severe adverse reactions were reported. Egger's test results exhibited no statistically significant pattern, a sign that publication bias was not present. In treating digestive system diseases, particularly stomach ache, Biling Weitong Granules resulted in improved VAS scores and symptom alleviation. Furthermore, it boosted clinical recovery and Hp eradication rates, all under a safe therapeutic regimen without any significant adverse effects. However, the original studies' quality was not up to par, hindered by specific limitations and shortcomings. Subsequent investigations necessitate the employment of consistent and standardized approaches for detecting and assessing outcome indicators, an emphasis on the rigorous design and implementation of studies, and a clear presentation of the medication's clinical safety profile, ultimately providing stronger clinical evidence for its practical application.

This study's objective was to examine the connection between traditional Chinese medicine (TCM) and a diminished risk of readmission among patients diagnosed with rheumatoid arthritis accompanied by hypoproteinemia (RA-H). A retrospective study of 2,437 rheumatoid arthritis patients from the First Affiliated Hospital of Anhui University of Chinese Medicine's database, covering the period from 2014 to 2021, revealed the presence of hypoproteinemia in 476 of these patients.